A detailed history of Cwm, LLC transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Cwm, LLC holds 7,884 shares of NBIX stock, worth $985,500. This represents 0.0% of its overall portfolio holdings.

Number of Shares
7,884
Previous 6,849 15.11%
Holding current value
$985,500
Previous $943,000 3.71%
% of portfolio
0.0%
Previous 0.0%

Shares

31 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 08, 2024

BUY
$114.58 - $153.15 $118,590 - $158,510
1,035 Added 15.11%
7,884 $908,000
Q2 2024

Jul 09, 2024

BUY
$130.86 - $143.19 $285,929 - $312,870
2,185 Added 46.85%
6,849 $943,000
Q1 2024

Apr 05, 2024

BUY
$130.4 - $143.74 $229,764 - $253,269
1,762 Added 60.72%
4,664 $643,000
Q4 2023

Feb 01, 2024

BUY
$106.07 - $132.76 $90,477 - $113,244
853 Added 41.63%
2,902 $382,000
Q3 2023

Oct 11, 2023

BUY
$94.02 - $117.1 $62,429 - $77,754
664 Added 47.94%
2,049 $231,000
Q2 2023

Aug 03, 2023

BUY
$89.53 - $104.87 $11,370 - $13,318
127 Added 10.1%
1,385 $131,000
Q1 2023

Apr 28, 2023

SELL
$94.11 - $123.02 $3,952 - $5,166
-42 Reduced 3.23%
1,258 $127,000
Q4 2022

Feb 01, 2023

BUY
$106.72 - $127.06 $5,015 - $5,971
47 Added 3.75%
1,300 $155,000
Q3 2022

Oct 27, 2022

BUY
$92.03 - $107.81 $22,547 - $26,413
245 Added 24.31%
1,253 $133,000
Q2 2022

Jul 28, 2022

BUY
$75.79 - $100.07 $35,697 - $47,132
471 Added 87.71%
1,008 $98,000
Q1 2022

Apr 21, 2022

BUY
$72.45 - $94.81 $23,763 - $31,097
328 Added 156.94%
537 $50,000
Q4 2021

Jan 31, 2022

SELL
$79.65 - $106.22 $3,584 - $4,779
-45 Reduced 17.72%
209 $18,000
Q1 2021

Sep 15, 2021

SELL
$87.57 - $119.4 $10,508 - $14,328
-120 Reduced 32.09%
254 $25,000
Q1 2021

Apr 27, 2021

BUY
$87.57 - $119.4 $10,508 - $14,328
120 Added 47.24%
374 $36,000
Q4 2020

Sep 15, 2021

BUY
$86.91 - $108.33 $14,253 - $17,766
164 Added 182.22%
254 $25,000
Q4 2020

Jan 27, 2021

SELL
$86.91 - $108.33 $14,253 - $17,766
-164 Reduced 64.57%
90 $9,000
Q3 2020

Sep 15, 2021

BUY
$96.16 - $135.15 $4,711 - $6,622
49 Added 23.9%
254 $25,000
Q3 2020

Oct 19, 2020

SELL
$96.16 - $135.15 $4,711 - $6,622
-49 Reduced 19.29%
205 $20,000
Q2 2020

Sep 15, 2021

BUY
$85.09 - $130.36 $20,421 - $31,286
240 Added 1714.29%
254 $25,000
Q2 2020

Jul 22, 2020

SELL
$85.09 - $130.36 $20,421 - $31,286
-240 Reduced 94.49%
14 $2,000
Q1 2020

Sep 15, 2021

BUY
$75.11 - $113.76 $17,876 - $27,074
238 Added 1487.5%
254 $25,000
Q1 2020

Apr 28, 2020

SELL
$75.11 - $113.76 $17,876 - $27,074
-238 Reduced 93.7%
16 $1,000
Q4 2019

Sep 14, 2021

BUY
$86.8 - $118.57 $13,454 - $18,378
155 Added 156.57%
254 $25,000
Q4 2019

Jan 27, 2020

SELL
$86.8 - $118.57 $13,454 - $18,378
-155 Reduced 61.02%
99 $11,000
Q3 2019

Sep 14, 2021

BUY
$83.82 - $101.5 $21,290 - $25,781
254 New
254 $25,000
Q3 2019

Oct 22, 2019

SELL
$83.82 - $101.5 $21,290 - $25,781
-254 Closed
0 $0
Q2 2019

Sep 14, 2021

BUY
$72.24 - $91.27 $18,348 - $23,182
254 New
254 $25,000
Q2 2019

Jul 31, 2019

SELL
$72.24 - $91.27 $18,348 - $23,182
-254 Closed
0 $0
Q1 2019

Sep 02, 2021

BUY
$69.31 - $91.53 $16,357 - $21,601
236 Added 1311.11%
254 $0
Q1 2019

Apr 22, 2019

SELL
$69.31 - $91.53 $415 - $549
-6 Reduced 25.0%
18 $2,000
Q4 2018

Jan 25, 2019

BUY
$68.32 - $124.36 $1,639 - $2,984
24 New
24 $2,000

Others Institutions Holding NBIX

About NEUROCRINE BIOSCIENCES INC


  • Ticker NBIX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 95,639,296
  • Market Cap $12B
  • Description
  • Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...
More about NBIX
Track This Portfolio

Track Cwm, LLC Portfolio

Follow Cwm, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cwm, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cwm, LLC with notifications on news.